NM Munoz, I Douglas, D Mayer, A Herrnreiter, X Zhu and AR Leff
Department of Medicine, University of Chicago, Illinois 60637, USA.

We studied the effects of the 5-lipoxygenase inhibition and sulfidopeptidyl leukotriene receptor antagonism on lumenal chemotaxis of eosinophils in 124 guinea pig tracheal explant preparations from 62 animals. Cell migration was assessed histologically and by differential cell count, and airway narrowing was measured by calibrated micrometry. Intralumenal instillation of the chemotaxin, formyl-met-leu-phe (FMLP) caused migration of 163,509 +/- 18,103 eosinophils/cm segment (eos/cm) versus 15,443 +/- 3,557 eos/cm for segments receiving vehicle only (p < 0.001). Coincubation of FMLP with zileuton, a selective inhibitor of 5- lipoxygenase, caused a concentration-related inhibition of eosinophil migration. At 10(-10) M zileuton, cell migration caused by FMLP was decreased by 57% and nearly complete reduction to 17,200 +/- 3,620 eos/cm resulted after 10(-6) M zileuton (p < 0.001 versus FMLP). Lumenal narrowing caused by FMLP (15.3 +/- 3.4%) was attenuated maximally to 1.15 +/- 2.51% after 10(-8) M zileuton (p < 0.02). In 36 preparations, concentration of leukotriene B4 (LTB4) was measured in treated tracheal perfusate. LTB4 secretion caused by FMLP was 6.4 +/- 0.48 pg/ml versus 3.32 +/- 0.89 pg/ml for buffer control at 5 min (p < 0.02) and was undetectable 120 min after activation with FMLP. Blockade of LTB4-receptor with the selective antagonist, LTB4 dimethyl amide, caused > 90% inhibition of eosinophil migration (p < 0.001). Comparable results were obtained with zafirlukast, an LTD4-receptor antagonist. Our data demonstrate that both LTB4 and LTD4 facilitate eosinophil migration from lamina propria to lumen caused by the chemotaxin, FMLP, and that LTB4-induced eosinophil migration is accompanied by initial lumenal secretion of LTB4.

This article has been cited by other articles:

				Y. Shiraishi, K. Asano, K. Niimi, K. Fukunaga, M. Wakaki, J. Kagyo, T. Takihara, S. Ueda, T. Nakajima, T. Oguma, et al. Cyclooxygenase-2/Prostaglandin D2/CRTH2 Pathway Mediates Double-Stranded RNA-Induced Enhancement of Allergic Airway Inflammation J. Immunol., January 1, 2008; 180(1): 541 - 549. [Abstract] [Full Text] [PDF]

				A. Murai, M. Abe, Y. Hayashi, N. Sakata, T. Katsuragi, and K. Tanaka Comparison Study between the Mechanisms of Allergic Asthma Amelioration by a Cysteinyl-Leukotriene Type 1 Receptor Antagonist Montelukast and Methylprednisolone J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 432 - 440. [Abstract] [Full Text] [PDF]

				A. Sandrini, I. M. Ferreira, C. Gutierrez, J. R. Jardim, N. Zamel, and K. R. Chapman Effect of Montelukast on Exhaled Nitric Oxide and Nonvolatile Markers of Inflammation in Mild Asthma Chest, October 1, 2003; 124(4): 1334 - 1340. [Abstract] [Full Text] [PDF]

				J. S. Erjefalt, M. Korsgren, M. Malm-Erjefalt, D. M. Conroy, T. J. Williams, and C. G. A. Persson Acute Allergic Responses Induce a Prompt Luminal Entry of Airway Tissue Eosinophils Am. J. Respir. Cell Mol. Biol., October 1, 2003; 29(4): 439 - 448. [Abstract] [Full Text] [PDF]

				D. R. S. Steiner, N. C. Gonzalez, and J. G. Wood Leukotriene B4 promotes reactive oxidant generation and leukocyte adherence during acute hypoxia J Appl Physiol, September 1, 2001; 91(3): 1160 - 1167. [Abstract] [Full Text] [PDF]

				S. S. Salvi, M. T. Krishna, A. P. Sampson, and S. T. Holgate The Anti-inflammatory Effects of Leukotriene-Modifying Drugs and Their Use in Asthma Chest, May 1, 2001; 119(5): 1533 - 1546. [Abstract] [Full Text] [PDF]

				D. J. FIGUEROA, R. M. BREYER, S. K. DEFOE, S. KARGMAN, B. L. DAUGHERTY, K. WALDBURGER, Q. LIU, M. CLEMENTS, Z. ZENG, G. P. O'NEILL, et al. Expression of the Cysteinyl Leukotriene 1 Receptor in Normal Human Lung and Peripheral Blood Leukocytes Am. J. Respir. Crit. Care Med., January 1, 2001; 163(1): 226 - 233. [Abstract] [Full Text]

				A. R Leff Role of leukotrienes in bronchial hyperresponsiveness and cellular responses in airways Thorax, October 1, 2000; 55(90002): 32S - 37. [Full Text]

				A. KANEHIRO, K. TAKEDA, A. JOETHAM, A. TOMKINSON, T. IKEMURA, C. G. IRVIN, and E. W. GELFAND Timing of Administration of Anti-VLA-4 Differentiates Airway Hyperresponsiveness in the Central and Peripheral Airways in Mice Am. J. Respir. Crit. Care Med., September 1, 2000; 162(3): 1132 - 1139. [Abstract] [Full Text]

				P. Kesteven Traveller's thrombosis Thorax, August 1, 2000; 55(90001): S32 - 36. [PDF]

				L. Lomnitski, A. Nyska, V. Ben-Shaul, R. R. Maronpot, J. K. Haseman, T. L. Harrus, M. Bergman, and S. Grossman Effects of Antioxidants Apocynin and the Natural Water-Soluble Antioxidant from Spinach on Cellular Damage Induced by Lipopolysaccaride in the Rat Toxicol Pathol, July 1, 2000; 28(4): 580 - 587. [Abstract] [PDF]

				L. Lomnitski, M. Carbonatto, V. Ben-Shaul, S. Peano, A. Conz, L. Corradin, R. R. Maronpot, S. Grossman, and A. Nyska The Prophylactic Effects of Natural Water-Soluble Antioxidant from Spinach and Apocynin in a Rabbit Model of Lipopolysaccharide-Induced Endotoxemia Toxicol Pathol, July 1, 2000; 28(4): 588 - 600. [Abstract] [PDF]

				J. S. ERJEFÄLT and C. G. A. PERSSON New Aspects of Degranulation and Fates of Airway Mucosal Eosinophils Am. J. Respir. Crit. Care Med., June 1, 2000; 161(6): 2074 - 2085. [Full Text]

				N. M. Munoz, G. A. van Seventer, R. T. Semnani, and A. R. Leff Augmentation of LTC4 synthesis in human eosinophils caused by CD3-stimulated Th2-like cells in vitro Am J Physiol Lung Cell Mol Physiol, June 1, 2000; 278(6): L1172 - L1179. [Abstract] [Full Text] [PDF]

				S.-E. DAHLEN Pharmacological Characterization of Leukotriene Receptors Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): S41 - 45. [Full Text] [PDF]

				A. R. LEFF Role of Leukotrienes in Bronchial Hyperresponsiveness and Cellular Responses in Airways Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): S125 - 132. [Full Text] [PDF]

				R G STIRLING and K F CHUNG Leukotriene antagonists and Churg-Strauss syndrome: the smoking gun Thorax, October 1, 1999; 54(10): 865 - 866. [Full Text]

				A. SANO, N. M. MUÑOZ, H. SANO, J. CHOI, X. ZHU, B. JACOBS, and A. R. LEFF Inhibition of cPLA2 Translocation and Leukotriene C4 Secretion by Fluticasone Propionate in Exogenously Activated Human Eosinophils Am. J. Respir. Crit. Care Med., June 1, 1999; 159(6): 1903 - 1909. [Abstract] [Full Text]

				M. A. Giembycz and M. A. Lindsay Pharmacology of the Eosinophil Pharmacol. Rev., June 1, 1999; 51(2): 213 - 340. [Abstract] [Full Text] [PDF]

				B. DAHLEN, E. NIZANKOWSKA, A. SZCZEKLIK, O. ZETTERSTROM, G. BOCHENEK, M. KUMLIN, L. MASTALERZ, G. PINIS, L. J. SWANSON, T. I. BOODHOO, et al. Benefits from Adding the 5-Lipoxygenase Inhibitor Zileuton to Conventional Therapy in Aspirin-intolerant Asthmatics Am. J. Respir. Crit. Care Med., April 1, 1998; 157(4): 1187 - 1194. [Abstract] [Full Text] [PDF]

				W. W. BUSSE Leukotrienes and Inflammation Am. J. Respir. Crit. Care Med., June 1, 1997; 157(6): 210S - 213. [Abstract] [Full Text]